Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

Mar 22 2018

• By Joseph Haas

Render illustration of Clinical Trial title on medical documents

Related Content

Was Rova-T Worth The High Price To AbbVie?

Jun 07 2016

New AbbVie Guidance Sets High Bar For Post-Humira Pipeline

Oct 28 2017

AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout

Apr 28 2016

AbbVie’s Cancer Expansion Is Paying Off

Jan 27 2017

Related Companies

AbbVie Inc.

Genentech, Inc.

Additional Topics

Clinical Trials Research & Development Business Strategies Deals Drug Approval Standards Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.